

MAP Pharmaceuticals, Inc.  
Form 8-K  
January 11, 2010

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 11, 2010**

**MAP PHARMACEUTICALS, INC.**

**(Exact Name of Registrant as Specified in its Charter)**

**Delaware**  
**(State or Other Jurisdiction**  
  
**of Incorporation)**

**001-33719**  
**(Commission File Number)**

**20-0507047**  
**(IRS Employer**  
  
**Identification No.)**

Edgar Filing: MAP Pharmaceuticals, Inc. - Form 8-K

**2400 Bayshore Parkway, Suite 200,**

**Mountain View, CA**  
**(Address of Principal Executive Offices)**

**94043**  
**(Zip Code)**

**Registrant's telephone number, including area code: (650) 386-3100**

**(Former Name or Former Address, if Changed Since Last Report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( *see* General Instruction A.2. below):

- ..  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ..  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ..  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ..  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

In a press release issued on January 11, 2010, MAP Pharmaceuticals, Inc. (the Company) announced that it had been informed by the U.S. Food and Drug Administration (FDA) that a second pivotal efficacy study of its LEVADEX product candidate for the potential treatment of migraine is not required for the Company's new drug application submission. Accordingly, the Company will not conduct a second pivotal efficacy study of its LEVADEX product candidate as previously planned. The Company also announced that it anticipates treatment of clinical subjects in the Company's remaining LEVADEX clinical trials to be completed in 2010. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits**

*(d) Exhibits*

**Exhibit**

<b>No.</b>	<b>Description</b>
99.1	Press Release of MAP Pharmaceuticals, Inc., dated January 11, 2010

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 11, 2010

**MAP PHARMACEUTICALS, INC.**

**By:** /s/ CHARLENE A. FRIEDMAN  
**Name:** Charlene A. Friedman  
**Title:** Vice President, General Counsel and Secretary

**INDEX TO EXHIBITS FILED WITH**

**THE CURRENT REPORT ON FORM 8-K DATED JANUARY 11, 2010**

<b>Exhibit</b>	<b>Description</b>
99.1	Press Release of MAP Pharmaceuticals, Inc., dated January 11, 2010